Skip to main content

Table 4 MCDA outcomes for drug-indication pairs appraised by AHTAPol between 2007 and 2011 (economic criteria included)

From: Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

No. Drug-indication pair Indication uniqueness Disease rarity Disease severity Adv.tech. Manufacturing technology Therapeutic alternative Sci. evid. clin.eff Benefits from use of medicine Cost effectiveness Budget impact Total number of points
  THRESHOLD 75 %           15 points
1 Nexavar (HCC) 1 2 2 0 2 2 2 0 1 1 13
2 Nplate 2 1 0 2 2 2 1 1 1 1 13
3 Cystadane 2 2 2 0 0 2 0 2 0 2 12
4 Increlex 2 0 0 2 2 2 1 1 0 2 12
5 Revlimid (MM/S) 1 0 2 1 0 2 2 1 1 2 12
6 Yondelis 1 1 2 2 0 2 2 0 1 0 11
7 Somavert 2 1 1 2 2 0 1 1 1 0 11
8 Tasigna 2 2 2 0 0 2 1 1 0 0 10
9 Torisel 1 0 2 2 2 0 1 1 0 1 10
  THRESHOLD 50 %           10 points
10 Vidaza 1 0 2 1 0 0 2 1 1 0 8
11 Atriance 1 0 2 1 0 2 1 0 0 1 8
12 Nexavar (RCC) 1 0 2 0 2 1 2 0 0 0 8
  THRESHOLD 25 %           5 points
  1. Adv. tech. Advancement of technology, Sci. evid. clin. eff. scientific evidence for clinical efficiency, NA no data available, HCC Hepatocellular carcinoma, GIST Malignant gastrointestinal stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma, ALL Ph+ Philadelphia chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases